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Letters

Europe, this practice is less consistently used in the United States.
However, these studies do not constitute level I evidence, and
thus, there is no worldwide consensus regarding endophthalmitis prophylaxis with cataract surgery.6

OBSERVATION

Limitations. This study is limited by its retrospective nature and
the possibility of selection bias. The mechanism of this increasing nonsusceptibility to fluoroquinolones is not fully understood, but it may be associated with widespread use of fluoroquinolones, use of antibiotics outside of the health care
sector, and emergence of intrinsic genetic factors promoting
resistance. Although this study involves only in vitro testing,
the clinical implications of this laboratory data requires further investigations.

Primary vitreoretinal lymphoma (PVRL) is a malignant large
B-cell lymphoma affecting the eye and brain, with 5-year
cumulative survival rate of 35% in those with brain involvement (68% in those without).1 Ocular involvement manifests with aggregated tumor cells in the vitreous, retina,
optic disc, and subretinal pigment epithelial space. Management involves treatment of both eyes and brain, and treatment options for the eye(s) include systemic chemotherapy,
external radiotherapy, or intravitreal injection of chemotherapy.
The most commonly used intravitreal medication for PVRL
is methotrexate. 2,3 Others have investigated intravitreal
rituximab.4 Herein, we report our experience with melphalan, a medication commonly used for treatment of vitreous
seeding from retinoblastoma,5,6 in 3 eyes of 2 patients with
PVRL. Both methotrexate and melphalan have been used for
retinoblastoma, and methotrexate requires approximately 25
injections/y, whereas melphalan needs fewer at 4 to 6 injections/y, the latter achieving retinoblastoma seed control in up
to 100% of cases.3,6
Melphalan is a well-established alkylating agent, developed in 1953 and used to treat several hematologic malignancies, including lymphoma, leukemia, and multiple
myeloma, as well as solid tumors including breast, ovarian,
and neural cancers.5 When used in the vitreous for retinoblastoma, filtered preparation of 20 μg/0.1 mL is sufficient
for tumor control.6 Owing to its effect on lymphoma and our
experience with this medication, we challenged PVRL with
melphalan.
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Intravitreal Melphalan for Treatment of Primary
Vitreoretinal Lymphoma: A New Indication
for an Old Drug

Methods | This retrospective investigation was approved by
the institutional review board of Wills Eye Hospital. Three
eyes of 2 patients with biopsy-confirmed PVRL were offered
standard treatment or intravitreal melphalan (low dose [10
μg/0.1 mL]). Following written consent, the medication was
injected into the vitreous using sterile technique. Clinical
features and outcomes were recorded.
Results | Case 1. A 92-year-old woman with vitrectomy-proven
bilateral PVRL (large B-cell lymphoma cytology) demonstrated severe vitreous tumor infiltration in the right eye and
mild infiltration in the left eye, with subretinal pigment epithelial tumor in the left eye (Figure 1). Visual acuity was
20/30 OD and 20/40 OS. She was treated with low-dose intravitreal melphalan (10 μg/0.1 mL) to both eyes. Following initial injection, complete clearance of vitreous tumor in both
eyes was noted within 3 weeks. During the 19-month followup, the right eye required 6 bimonthly injections for minor
seed recurrence, and the left eye remained stable without
recurrence. There were no toxicities in either eye, but the left
eye showed stable focal subfoveal fluid, with mild macular
edema at presentation and throughout her course. Final
visual acuity was 20/50 OU.
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Figure 1. Case 1: A 92-Year-Old Woman
A Baseline fundus photograph, right eye

B

C

Baseline optical coherence tomography, right eye

D Baseline optical coherence tomography, left eye

E

1-mo Follow-up, right eye

G 13-mo Follow-up, right eye

F

Baseline fundus photograph, left eye

1-mo Follow-up, left eye

H 13-mo Follow-up, left eye

Case 2. A 65-year-old man with chronic uveitis in both eyes and
vitrectomy-proven PVRL (large B-cell lymphoma cytology)
demonstrated moderate vitreous tumor in both eyes (Figure 2).
At treatment, visual acuity was 20/150 OD and 20/400 OS. The
right eye was treated with intravitreal melphalan and the left
eye with intravitreal methotrexate. The right eye demonstrated rapid improvement of visual acuity within 2 days (per
patient observation) and measured 20/50 at 1 month, requiring no further melphalan injections over 16 months follow816

A 92-year-old woman with visual
acuity of 20/30 OD and 20/40 OS
and biopsy-proven posterior
vitreoretinal lymphoma showed
dense vitreous infiltrate in the right
eye (A) and mild vitreous infiltrate in
the left eye (B) with peripheral
multifocal retinal pigment epithelial
infiltrates. Optical coherence
tomography showed hazy view of the
fovea in the right eye from vitreous
opacification and intraretinal edema
with shallow subretinal fluid in the
left eye (C and D). Following 1
injection of intravitreal melphalan to
each eye, complete clearance of
vitreous cells was documented in
both eyes (E and F) at 1 month.
Optical coherence tomography
showed a normal right fovea (G) and
unchanged edema and subretinal
fluid in the left eye (H). Final visual
acuity was 20/50 OU at 16 months’
follow-up.

up, whereas the left eye showed slower response and a total
of 19 injections of methotrexate over 11 months follow-up. Both
eyes showed intermittent cystoid macular edema from uveitis, and final visual acuity was 20/50 OD and 20/70 OS.
A summary of the 3 eyes with PVRL revealed rapid response to low-dose intravitreal melphalan, with complete vitreous tumor clearance in 2 cases following a single injection
and tumor control following multiple injections in one case.
There was no retinal toxicity.
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Figure 2. Case 2: A 65-Year-Old Man
A Baseline fundus photograph, right eye

B

C

Baseline optical coherence tomography, right eye

D Baseline optical coherence tomography, left eye

E

Fundus photograph following melphalan injection,
right eye

F

G 13-mo Follow-up, right eye

Baseline fundus photograph, left eye

Fundus photograph following 13 methotrexate injections,
left eye

H 13-mo Follow-up, left eye

Discussion | These 3 eyes with PVRL demonstrate that intravitreal melphalan, currently used for vitreous seeds from
retinoblastoma,6 can result in vitreous lymphoma control with
few injections. Given the limited number of cases and relatively short follow-up, further investigation seems warranted to determine efficacy, safety, and appropriate treatment regimen.
jamaophthalmology.com

A 65-year-old man with visual acuity
of 20/150 OD and 20/400 OS with
chronic posterior uveitis and
biopsy-proven posterior vitreoretinal
lymphoma showed moderate
vitreous infiltrate in both eyes at the
time of treatment (A and B). Optical
coherence tomography showed trace
macular edema in the right eye (C)
and shallow subretinal debris in the
left eye (D). Following a single
melphalan injection in the right eye
(E), complete clearance of vitreous
cells was documented and persisted
until last examination. Following 13
injections of methotrexate in the left
eye (F), vitreous clearance was noted.
At last examination, optical
coherence tomography documented
trace foveal edema in the right eye
(G) and moderate macular edema in
the left eye (H). At 13 months, final
visual acuity was 20/50 OD and
20/70 OS.
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I was the physician who conducted the medical encounters for patients with a prehistory and I can attest to the improvement in medical record accuracy. I was able to enter the
examination room, greet the patient, and then read the patient’s narrative, all of which was documented in the record. I
finished the history with specific questions and then performed a pertinent examination. Any medical decision making occurring readily transformed to shared decision making
because the patients were engaged and I was relieved of clerical burdens.
After seeing the physician, each patient was given a paper copy of the encounter note at the checkout window. Patients were instructed to go home, read their record, and score
it with an anonymous survey. Patients who completed a prehistory form in preparation for a medical encounter reported
feeling better heard and understood.
Medical record inaccuracy could adversely affect patient
safety and data analytics. These comments suggest that a prehistory form potentially may be a means of improving health
record accuracy.
Michael John Warner, DO
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Editorial Note: This letter was shown to the corresponding author of the
original article, who declined to reply on behalf of the authors.

COMMENT & RESPONSE

Patient Coauthored History Could Improve
Health Record Accuracy
1

To the Editor The article by Valikodath et al showcases a problem with modern health records: documentation does not always match the patient’s concerns. The authors conclude that
electronic medical record data may not provide a comprehensive resource for clinical practice or “big data” research.
I agree that a solution may come from patient-generated
information. In a previous report,2 patients were invited to
complete a replica of a history as defined by the Centers for
Medicare and Medicaid Services. Patients completed a 3-page
prehistory form with approximately 30 questions in a structured format that included chief complaint(s), a history of present illness, the status of chronic condition(s), a review of systems, and a past family social history.3
A total of 263 patients who were aged 14 to 94 years completed the form in preparation for a family physician visit. On
arriving to the office, the prehistory form was scanned into the
electronic health record as a document and the content was
transcribed by a staff member into the history component of
the encounter note. The prehistory was recognized as a written request to amend the health record per the Health Insurance Portability and Accountability Act Privacy Rule (45 C.F.R.
§ 164.526).
818

1. Valikodath NG, Newman-Casey PA, Lee PP, Musch DC, Niziol LM, Woodward
MA. Agreement of ocular symptom reporting between patient-reported
outcomes and medical records. JAMA Ophthalmol. 2017;135(3):225-231, 231.
2. Warner MJ, Simunich TJ, Warner MK, Dado J. Use of patient-authored
prehistory to improve patient experiences and accommodate federal law. J Am
Osteopath Assoc. 2017;117(2):78-84.
3. Patient Advocacy Initiatives. PreHistory forms available for free at non-profit:
http://www.PatientAdvocacyInitiatives.org. Accessed February 16, 2017.

Incorporating Clinical, Histological,
and Genetic Parameters for Choroidal
Melanoma Prognostication
Walter et al1 recently reported that tumor diameter measurement enhances the prediction of metastatic disease from class
2 uveal melanoma (UM), as classified with gene expression profiling. They advocate combining these 2 predictors when estimating prognoses.
We agree with this recommendation. Since 2007, we have
published several articles emphasizing the importance of combining clinical, histologic, and genetic survival predictors when
estimating a prognosis for UM posttreatment.2 We developed
an online prognostic tool predicting survival using multivariable analyses, also accounting for age and sex.2 Walter et al1
have not cited these articles, so their Discussion does not interpret their results by taking into consideration all other relevant evidence in the literature.
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